Cancer Treatments
From Atomic Analysis to Atomic Medicine
Atomic Oncology Pty Limited has patented a novel connection between the atomic properties of any cancer and its susceptibility to therapeutic intervention via ultra-precise radiation therapy. This connection is projected to provide a cure rate that exceeds chemotherapy, immunotherapy or drug-based therapies for most cancer types.
The connection is based on unique non-enzymatic manganese chemistry originally described in highly radiation resistant bacteria. This connection does not overlap with any genomic or proteomic Intellectual Property. It is a first-in class process that reveals the most dangerous attributes of any cancer and its greatest vulnerability. Our technology involves vaporizing a cancer sample using laser ablation and measuring its atomic content and 3D distribution via Inductively Coupled Plasma - Mass Spectrometry. The quantitative output is a cartographic atomic image, generated in minutes, which provides unprecedented insights into what makes any cancer most sensitive to radiation treatment, and thus provides the highest chance of patient cure.
Our process:
is free from all prior patent art
has no overlap with any genomic, proteomic or drug IP
is unique to each patient’s tumour
For the first time, the connection between an atomic diagnostic and its direct implementation in patients via customized precision external beam therapy, or brachytherapy, has become a clinical reality.
This unique discovery is placed into perspective by the Nobel prize winning biochemist, Edmond Fischer at the University of Washington, Seattle, WA, USA.
“Studies derived from manganese-based atomic research have resulted in a profound new understanding of cancer radiotherapy. The data obtained are totally unexpected. They are of fundamental importance and will certainly have deep implications for patient treatment”.